UPM Pharmaceuticals to buy Pfizer’s Tennessee manufacturing facility

With the acquisition of 500,000ft² commercial manufacturing facility, UPM expects to expand capacity for production of solid oral dosage tablets and capsules, in addition to semi-solid creams and ointments.

The plant facilitates comprehensive technology transfer support, pilot plant scale-up capabilities, analytical and microbial testing.

Pfizer strategy and transitioning sites vice president John Kelly said, "UPM leaders have experience with this site, and are familiar with our colleagues and the products we manufacture there, they share our commitment to quality and have a long history of success."

Under the terms of the deal, the manufacturing activities of Pfizer’s current portfolio will be carried out by UPM for two years.

UPM president James Gregory said, "The new facility will give UPM the capability to annually produce 3.5 billion tablets and 680 million capsules; this will be a dramatic growth opportunity for our company and our clients."